If you liked this article you might like

Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy
High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids